Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
WITHDRAWN
NCT04674735
PHASE1
Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
Sponsor: Apsen Farmaceutica S.A.
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the safety of APSLXR in participants with Meniere's disease or other Verigo of vestibular origin. Pharmacokinetics will also be evaluated in a small group.
Official title: Multicentre, Open Label, Phase I Clinical Trial to Evaluate the Safety of APSLXR for the Treatment of Vertigo of Vestibular Origin or Meniere's Disease
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2023-01
Completion Date
2025-06
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
APSLXR
Oral coated tablets once a day for 60 days.